Cardurion Pharmaceuticals logo

Cardurion Pharmaceuticals

Translating the science of cardiac myocyte signaling pathways into groundbreaking therapeutics

80 employees · est. 2017 · Burlington, United States

VS
Myogen logo

Myogen

Advancing cardiovascular health with innovative small molecule therapeutics for unmet medical needs.

est. 1996

Myogen is the older company (2017 vs 1996).

Side-by-Side Comparison

Cardurion Pharmaceuticals Myogen
Founded
2017 1996 older
Headquarters
Burlington, United States Not tracked yet
Employees
80 Not tracked yet
Industry
Biotechnology, Health Care, Pharmaceutical Biopharma, Biotechnology, Health Care
Funding Stage
Series B Series D
Total Funding
$603.20M $187.77M
Funding Rounds
5 5
Services
Research and Development of Cardiovascular Drugs, Clinical Programs in PDE9 and CaMKII, In-house Drug Discovery, Clinical Study Evaluation Not tracked yet
Target Customers
Patients with Cardiovascular Disease, Healthcare Providers, Pharmaceutical Companies, Biotechnology Investors Not tracked yet
Taxonomy
Cardurion Pharmaceuticals, Cardiac Myocyte Signaling Pathways, PDE9 Inhibition, CaMKII Inhibition, Cardiovascular Therapeutics, Heart Failure Treatment, Biotechnology Company, Clinical Programs, Cardiovascular Diseases, Partnerships, Investors, Bain Capital, Takeda Pharmaceutical, Astellas, Drug Discovery, Boston-based Company Biopharmaceutical Company, Cardiovascular Health, Small Molecule Therapeutics, Discovery, Development, Commercialization, Clinical Expertise, Cardiovascular Disorders, Biology Of Cardiovascular Disease, Clinical Development Expertise, Novel Therapies, Licensing, Acquisition, Unmet Medical Needs
Website
cardurion.com myogen.com
Cardurion Pharmaceuticals logo

About Cardurion Pharmaceuticals

Cardurion Pharmaceuticals, founded in 2017, is a biotechnology and pharmaceutical company targeting advancements in cardiovascular health through innovative drug discovery. The company is renowned for its expertise in translating cardiac myocyte signaling pathways into groundbreaking therapeutics, s...

Myogen logo

About Myogen

Myogen is a biopharmaceutical company founded in 1996, dedicated to advancing cardiovascular health with innovative small molecule therapeutics. Their slogan "Advancing cardiovascular health with innovative small molecule therapeutics for unmet medical needs" reflects their mission. The company focu...

We will tell you when either one moves

BounceWatch watches Cardurion Pharmaceuticals and Myogen for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Cardurion Pharmaceutic... and Myogen — by email.

Frequently Asked Questions

Cardurion Pharmaceuticals — Translating the science of cardiac myocyte signaling pathways into groundbreaking therapeutics. Myogen — Advancing cardiovascular health with innovative small molecule therapeutics for unmet medical needs.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Cardurion Pharmaceuticals has raised $603.20M while Myogen has raised $187.77M.
Cardurion Pharmaceuticals and Myogen operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Cardurion Pharmaceuticals with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at Cardurion Pharmaceuticals on 12 Sep 2024, and Myogen on 26 Jul 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy